Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Yong Woo | - |
dc.contributor.author | Kim, Sang Yoon | - |
dc.contributor.author | Kwon, Ick Chan | - |
dc.contributor.author | Kim, In-San | - |
dc.date.accessioned | 2024-01-20T10:31:14Z | - |
dc.date.available | 2024-01-20T10:31:14Z | - |
dc.date.created | 2021-09-05 | - |
dc.date.issued | 2014-02-10 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/127096 | - |
dc.description.abstract | Tumors begin with a single cell, but as each tumor grows and evolves, it becomes a wide collection of clones that display remarkable heterogeneity in phenotypic features, which has posed a big challenge to current targeted anticancer therapy. Intra-and inter-tumoral heterogeneity is attributable in part to genetic mutations but also to adaptation and evolution of tumors to heterogeneity in tumor microenvironments. If tumors are viewed not only as a disease but also as a complex adaptive system(CAS), tumors should be treated as such and a more systemic approach is needed. Some of many tumors therapeutic strategies are discussed here from a view of a tumor as CAS, which can be collectively called a complex adaptive therapeutic strategy (CATS). The central theme of CATS is based on three intermediate concepts: i) disruption of artifacts, ii) disruption of connections, and iii) reprogramming of cancer-immune dynamics. Each strategy presented here is a piece of the puzzle for CATS. Although each piece by itself may be neither novel nor profound, an assembled puzzle could be a novel and innovative cancer therapeutic strategy. (C) 2013 Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.publisher | ELSEVIER | - |
dc.subject | DRUG | - |
dc.subject | HETEROGENEITY | - |
dc.subject | PENETRATION | - |
dc.subject | ULTRASOUND | - |
dc.subject | EFFICACY | - |
dc.subject | DELIVERY | - |
dc.title | Complex adaptive therapeutic strategy (CATS) for cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jconrel.2013.12.017 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.175, pp.43 - 47 | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 175 | - |
dc.citation.startPage | 43 | - |
dc.citation.endPage | 47 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000330121200006 | - |
dc.identifier.scopusid | 2-s2.0-84891773419 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | DRUG | - |
dc.subject.keywordPlus | HETEROGENEITY | - |
dc.subject.keywordPlus | PENETRATION | - |
dc.subject.keywordPlus | ULTRASOUND | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordAuthor | Tumor heterogeneity | - |
dc.subject.keywordAuthor | Complex adaptive system (CAS) | - |
dc.subject.keywordAuthor | Induced phenotype | - |
dc.subject.keywordAuthor | Tumor network | - |
dc.subject.keywordAuthor | Cancer immunotherapy | - |
dc.subject.keywordAuthor | Nanoparticle | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.